statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ProMIS Neurosciences, Inc. (NASDAQ:PMN - Free Report) - Leede Jones Gab cut their FY2024 EPS estimates for ProMIS Neurosciences in a research note issued to investors on Wednesday, April 3rd...

Leede Jones Gab Weighs in on ProMIS Neurosciences, Inc.'s FY2024 Earnings (NASDAQ:PMN)

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

ProMIS Neurosciences, Inc. (NASDAQ:PMN - Free Report) - Equities research analysts at Leede Jones Gab issued their FY2028 earnings per share (EPS) estimates for ProMIS Neurosciences in a research...

ProMIS Neurosciences, Inc. Expected to Earn FY2028 Earnings of $0.62 Per Share (NASDAQ:PMN)

Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE...

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Adds Key U.S. and International Patent Allowances to Further Protect the Company's Monoclonal Antibody Therapeutic for the Treatment of Alzheimer's DiseaseCAMBRIDGE, Massachusetts and TORONTO...

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson's disease and Dementia with Lewy bodiesCAMBRIDGE, Massachusetts and TORONTO...

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company...

ProMIS Neurosciences Issues Letter to Shareholders

Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive OfficerCAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences...

ProMIS Neurosciences, Inc. Announces Leadership Transition

ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.

Volume	13.00
52-Wk High	$8.95
52-Wk Low	$0.95

PMN ProMIS Neurosciences

About

Feed

News

Earnings

Fundamentals